All In MedTech

Device Trial Radar · NCT02100683

Nit-Occlud PDA Post-Approval Study

Last checked: Nov 20, 2026Latest source record: Oct 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

184

Actual

Start

Aug 2014

Primary completion

Nov 20, 2019

Study completion Aug 10, 2022

Sponsor

Lead sponsor
PFM Medical, IncNot on our public-company list
Sponsor type
Industry
Collaborators
Bright Research Partners
First posted
Apr 1, 2014

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 6 months, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Nit-Occlud PDA Post-Approval Study is designed to continue to evaluate the safety and effectiveness of the device in the post-approval phase.

Conditions

  • Patent Ductus Arteriosus (PDA)

Interventions

  • PDA CoilDevice

    The Nit-Occlud PDA is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter \< 4 mm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Serious Device and/or Procedure Related Adverse Events as a Measure of SafetyTime frame: 24 months (2 year)

1 more outcomes with a free account

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Loma Linda University Medical Center

    Loma Linda, California

10 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.